Proteomic analysis of glioblastomas: What is the best brain control sample?

Journal of Proteomics

Volumn 85, Issue , 2013, Pages 165-173

  Lemée, Jean Michel ^a,b   Com, Emmanuelle ^c   Clavreul, Anne ^a,b   Avril, Tony ^d,e,f   Quillien, Véronique ^d,e,f   de Tayrac, Marie ^e,f,g   Pineau, Charles ^c   Menei, Philippe ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d CENTRE EUGÈNE MARQUIS   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

^f UNIVERSITÉ DE RENNES 1   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Epilepsy; Glioblastoma; ICPL; Proteomic

Indexed keywords

ISOTOPE; PROTEIN; PROTEOME;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BRAIN; BRAIN SURGERY; BRAIN TUMOR; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; EPILEPSY; EPILEPSY SURGERY BRAIN SAMPLE; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE CODED PROTEIN LABELING; ISOTOPE LABELING; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PERITUMORAL BRAIN ZONE SAMPLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUMOR VOLUME; WESTERN BLOTTING;

BRAIN NEOPLASMS; EPILEPSY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878361572     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.04.031     Document Type: Article

References (41)

1. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
2. Wen P.Y., Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359:492-507.
3. Giese A., Kucinski T., Knopp U., Goldbrunner R., Hamel W., Mehdorn H.M., et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 2004, 66:351-360.
4. Lefranc F., Brotchi J., Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005, 23:2411-2422.
5. Liang B.C., Thornton A.F., Sandler H.M., Greenberg H.S. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991, 75:559-563.
6. Iacob G., Dinca E.B. Current data and strategy in glioblastoma multiforme. J Med Life 2009, 2:386-393.
7. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
8. Vitucci M., Hayes D.N., Miller C.R. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer 2011, 104:545-553.
9. Carlsson A., Persson O., Ingvarsson J., Widegren B., Salford L., Borrebaeck C.A., et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl 2010, 4:591-602.
10. Com E., Clavreul A., Lagarrigue M., Michalak S., Menei P., Pineau C. Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. J Proteomics 2012, 75:3898-3913.
11. Niclou S.P., Fack F., Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics 2010, 73:1823-1838.
12. Khalil A.A. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 2007, 98:201-213.
13. Schmidt A., Kellermann J., Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 2005, 5:4-15.
14. Kellermann J. ICPL-isotope-coded protein label. Methods Mol Biol 2008, 424:113-123.
15. Lottspeich F., Kellermann J. ICPL labeling strategies for proteome research. Methods Mol Biol 2011, 753:55-64.
16. Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T., Pfaff E., Jacob K., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
17. Sturm D., Witt H., Hovestadt V., Khuong-Quang D.A., Jones D.T., Konermann C., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22:425-437.
18. Ousman S.S., Tomooka B.H., van Noort J.M., Wawrousek E.F., O'Connor K.C., Hafler D.A., et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007, 448:474-479.
19. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
20. Chin D., Boyle G.M., Williams R.M., Ferguson K., Pandeya N., Pedley J., et al. Alpha B-crystallin, a new independent marker for poor prognosis in head and neck cancer. Laryngoscope 2005, 115:1239-1242.
21. Yaung J., Kannan R., Wawrousek E.F., Spee C., Sreekumar P.G., Hinton D.R. Exacerbation of retinal degeneration in the absence of alpha crystallins in an in vivo model of chemically induced hypoxia. Exp Eye Res 2008, 86:355-365.
22. Louapre P., Grongnet J.F., Tanguay R.M., David J.C. Effects of hypoxia on stress proteins in the piglet heart at birth. Cell Stress Chaperones 2005, 10:17-23.
23. Dimberg A., Rylova S., Dieterich L.C., Olsson A.K., Schiller P., Wikner C., et al. alphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. Blood 2008, 111:2015-2023.
24. Han S.R., Shin C., Park S., Rhyu S., Park J., Kim Y.I. Differential expression of activating transcription factor-2 and c-Jun in the immature and adult rat hippocampus following lithium-pilocarpine induced status epilepticus. Yonsei Med J 2009, 50:200-205.
25. Houser C.R., Zhang N., Peng Z., Huang C.S., Cetina Y. Neuroanatomical clues to altered neuronal activity in epilepsy: from ultrastructure to signaling pathways of dentate granule cells. Epilepsia 2012, 53(Suppl. 1):67-77.
26. Clavreul A., Etcheverry A., Chassevent A., Quillien V., Avril T., Jourdan M.L., et al. Isolation of a new cell population in the glioblastoma microenvironment. J Neurooncol 2012, 106:493-504.
27. Skold K., Svensson M., Norrman M., Sjogren B., Svenningsson P., Andren P.E. The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: stathmin 2-20 and peptides as sample quality indicators. Proteomics 2007, 7:4445-4456.
28. Collet B., Guitton N., Saikali S., Avril T., Pineau C., Hamlat A., et al. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci 2011, 9:16.
29. Brennan C., Momota H., Hambardzumyan D., Ozawa T., Tandon A., Pedraza A., et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009, 4:e7752.
30. Melchior K., Tholey A., Heisel S., Keller A., Lenhof H.P., Meese E., et al. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. J Proteome Res 2009, 8:4604-4614.
31. Park C.K., Jung J.H., Moon M.J., Kim Y.Y., Kim J.H., Park S.H., et al. Tissue expression of manganese superoxide dismutase is a candidate prognostic marker for glioblastoma. Oncology 2009, 77:178-181.
32. Mustafa D.A., Burgers P.C., Dekker L.J., Charif H., Titulaer M.K., Smitt P.A., et al. Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels. Mol Cell Proteomics 2007, 6:1147-1157.
33. Odreman F., Vindigni M., Gonzales M.L., Niccolini B., Candiano G., Zanotti B., et al. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 2005, 4:698-708.
34. Furuta M., Weil R.J., Vortmeyer A.O., Huang S., Lei J., Huang T.N., et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 2004, 23:6806-6814.
35. Schwartz S.A., Weil R.J., Thompson R.C., Shyr Y., Moore J.H., Toms S.A., et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005, 65:7674-7681.
36. Chumbalkar V.C., Subhashini C., Dhople V.M., Sundaram C.S., Jagannadham M.V., Kumar K.N., et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005, 5:1167-1177.
37. Iwadate Y., Sakaida T., Hiwasa T., Nagai Y., Ishikura H., Takiguchi M., et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004, 64:2496-2501.
38. Schwartz S.A., Weil R.J., Johnson M.D., Toms S.A., Caprioli R.M. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res 2004, 10:981-987.
39. Hiratsuka M., Inoue T., Toda T., Kimura N., Shirayoshi Y., Kamitani H., et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003, 309:558-566.
40. Hobbs S.K., Shi G., Homer R., Harsh G., Atlas S.W., Bednarski M.D. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 2003, 18:530-536.
41. Chakravarti A., Delaney M.A., Noll E., Black P.M., Loeffler J.S., Muzikansky A., et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001, 7:2387-2395.